Clinical Trial

A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Name: A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer — clinical trial record (NCT07348861)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase II, prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with iparomlimab and tuvonralimab as neoadjuvant therapy in patients with locally advanced cervical cancer

Trial Details

NCT Number	NCT07348861
Lead Sponsor	Zheng Min Collaborators: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd.
Conditions	Cervical Cancer
Enrollment	25 participants
Start Date	2026-02-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-16